36 related articles for article (PubMed ID: 24678017)
1.
Beyzaei Z; Geramizadeh B; Bagheri Z; Karimzadeh S; Shojazadeh A
Front Immunol; 2020; 11():613128. PubMed ID: 33424868
[TBL] [Abstract][Full Text] [Related]
2. Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease.
Marfà S; Crespo G; Reichenbach V; Forns X; Casals G; Morales-Ruiz M; Navasa M; Jiménez W
PLoS One; 2014; 9(10):e109254. PubMed ID: 25275549
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Modifiable Risk Factors for de novo Malignancies After Living Donor Liver Transplantation.
Choudhary NS; Podisatti A; Dhampalwar S; Singh KA; Saraf N; Soin AS
J Clin Exp Hepatol; 2024; 14(3):101362. PubMed ID: 38495075
[No Abstract] [Full Text] [Related]
4. A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis.
Rabindranath M; Zaya R; Prayitno K; Orchanian-Cheff A; Patel K; Jaeckel E; Bhat M
Transplant Direct; 2023 Nov; 9(11):e1547. PubMed ID: 37854023
[TBL] [Abstract][Full Text] [Related]
5. Detailed Analysis of Simultaneous Renal and Liver Allografts in the Presence of DSA.
O'Leary JG; Farris AB; Gebel HM; Asrani SK; Askar M; Garcia V; Snipes GJ; Lo DJ; Knechtle SJ; Klintmalm GB; Demetris AJ
Transplant Direct; 2023 Aug; 9(8):e1500. PubMed ID: 37456590
[TBL] [Abstract][Full Text] [Related]
6. The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume.
Goto R; Ito M; Kawamura N; Watanabe M; Ganchiku Y; Kamiyama T; Shimamura T; Taketomi A
Immun Inflamm Dis; 2022 Mar; 10(3):e586. PubMed ID: 35064772
[TBL] [Abstract][Full Text] [Related]
7. Chronic rejection after liver transplantation: Opening the Pandora's box.
Angelico R; Sensi B; Manzia TM; Tisone G; Grassi G; Signorello A; Milana M; Lenci I; Baiocchi L
World J Gastroenterol; 2021 Dec; 27(45):7771-7783. PubMed ID: 34963740
[TBL] [Abstract][Full Text] [Related]
8. Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies.
Gül-Klein S; Hegermann H; Röhle R; Schmelzle M; Tacke F; Schöning W; Öllinger R; Dziodzio T; Maier P; Plewe JM; Horst D; Sauer IM; Pratschke J; Lachmann N; Eurich D
J Inflamm Res; 2021; 14():2697-2712. PubMed ID: 34188517
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Short- and Long-term Liver Graft Survival in the United Kingdom: Development of a UK Donor Liver Index.
Collett D; Friend PJ; Watson CJ
Transplantation; 2017 Apr; 101(4):786-792. PubMed ID: 27906826
[TBL] [Abstract][Full Text] [Related]
10. Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers.
Pratschke S; Arnold H; Zollner A; Heise M; Pascher A; Schemmer P; Scherer MN; Bauer A; Jauch KW; Werner J; Guba M; Angele MK
Transplant Direct; 2016 Jun; 2(6):e76. PubMed ID: 27500266
[TBL] [Abstract][Full Text] [Related]
11. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.
Cuadrado A; San Segundo D; López-Hoyos M; Crespo J; Fábrega E
World J Gastroenterol; 2015 Oct; 21(39):11016-26. PubMed ID: 26494958
[TBL] [Abstract][Full Text] [Related]
13. ABO-compatible liver allograft antibody-mediated rejection: an update.
Demetris AJ; Zeevi A; O'Leary JG
Curr Opin Organ Transplant; 2015 Jun; 20(3):314-24. PubMed ID: 25944231
[TBL] [Abstract][Full Text] [Related]
14. The role of donor-specific HLA alloantibodies in liver transplantation.
O'Leary JG; Demetris AJ; Friedman LS; Gebel HM; Halloran PF; Kirk AD; Knechtle SJ; McDiarmid SV; Shaked A; Terasaki PI; Tinckam KJ; Tomlanovich SJ; Wood KJ; Woodle ES; Zachary AA; Klintmalm GB
Am J Transplant; 2014 Apr; 14(4):779-87. PubMed ID: 24580828
[TBL] [Abstract][Full Text] [Related]
15. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.
O'Leary JG; Kaneku H; Jennings L; Susskind BM; Terasaki PI; Klintmalm GB
Liver Transpl; 2014 Jun; 20(6):655-63. PubMed ID: 24678017
[TBL] [Abstract][Full Text] [Related]
16. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts.
OʼLeary JG; Demetris AJ; Philippe A; Freeman R; Cai J; Heidecke H; Smith C; Hart B; Jennings LW; Catar R; Everly M; Klintmalm GB; Dragun D
Transplantation; 2017 Oct; 101(10):2399-2409. PubMed ID: 28665894
[TBL] [Abstract][Full Text] [Related]
17. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.
O'Leary JG; Kaneku H; Jennings LW; Bañuelos N; Susskind BM; Terasaki PI; Klintmalm GB
Liver Transpl; 2013 Sep; 19(9):973-80. PubMed ID: 23780820
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
Vandevoorde K; Ducreux S; Bosch A; Guillaud O; Hervieu V; Chambon-Augoyard C; Poinsot D; André P; Scoazec JY; Robinson P; Boillot O; Dubois V; Dumortier J
Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression.
Maluf DG; Archer KJ; Villamil F; Stravitz RT; Mas V
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):445-58. PubMed ID: 20678018
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
